Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Xingxing Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Army Medical University (Third Military Medical University), Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Colitis, Sepsis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Sacituzumab govitecan is widely used for the treatment of breast cancer and urothelial carcinoma, but available information regarding adverse events (AEs) is limited. We aim to explore the AE induced by sacituzumab govitecan by mining the FDA Adverse Event Reporting System (FAERS) database. The association between sacituzumab govitecan and AEs was evaluated using the information component. A multivariate logistic regression analysis was conducted for all identified signals to explore the risk factors associated with AEs leading to hospitalization. In total, 1,884 reports related to sacituzumab govitecan were retrieved, and 114 AE signals involving 20 systems were identified. The median time for onset of AEs was ~ 6–7 days after initiating treatment with sacituzumab govitecan, with over 80% of AEs occurring within 30 days. Subgroup analysis revealed that 14 signals were reported in men and 110 in women. There were 58 signals reported in patients under 65 following the use of sacituzumab govitecan, 59 signals in patients over 65, and 31 signals were present in both groups. Multivariable analysis showed that being male and the occurrence of colitis, pneumonitis, febrile neutropenia, pyrexia, sepsis, dehydration, and diarrhea were risk factors leading to hospitalization with an area under the curve (AUC) of 0.89. Additionally, sensitivity analysis revealed that this study had good robustness. This is the first retrospective analysis based on FAERS to review the safety of sacituzumab govitecan. The results highlight the need to closely monitor adverse reactions such as neutropenia, diarrhea, colitis, and sepsis when using sacituzumab govitecan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Army Medical University (Third Military Medical University), Chongqing, China.
- Department of Pharmacy, Nan'an People's Hospital of Chongqing, Chongqing, China.
ORCID-Profile: Xingxing Li, Lin Zhang, Sang Hu, Dan Liu, Bin Hu, Jie Ran, Xiaofang Lin, Wei Mao, Jing Hu
Zitieren
APA
Li, X., Zhang, L., Hu, S., Liu, D., Hu, B., Ran, J., Lin, X., Mao, W., & Hu, J. (2024). Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3098
Vancouver
Li X, Zhang L, Hu S, Liu D, Hu B, Ran J, et al. Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3098
BibTeX
@article{Li2024,
author = {Li, Xingxing and Zhang, Lin and Hu, Sang and Liu, Dan and Hu, Bin and Ran, Jie and Lin, Xiaofang and Mao, Wei and Hu, Jing},
title = {Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3098}
}
EUVIMED